297 related articles for article (PubMed ID: 21482709)
1. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17.
Agaugué S; Carosella ED; Rouas-Freiss N
Blood; 2011 Jun; 117(26):7021-31. PubMed ID: 21482709
[TBL] [Abstract][Full Text] [Related]
2. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance.
Loumagne L; Baudhuin J; Favier B; Montespan F; Carosella ED; Rouas-Freiss N
Int J Cancer; 2014 Nov; 135(9):2107-17. PubMed ID: 24623585
[TBL] [Abstract][Full Text] [Related]
3. HLA-G expression in malignant melanoma.
Rebmann V; Wagner S; Grosse-Wilde H
Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
[TBL] [Abstract][Full Text] [Related]
4. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts.
Zhang W; Liang S; Wu J; Horuzsko A
Transplantation; 2008 Oct; 86(8):1125-34. PubMed ID: 18946352
[TBL] [Abstract][Full Text] [Related]
5. HLA-G: on the track of immunological functions.
Le Bouteiller P
Eur J Immunogenet; 1997 Oct; 24(5):397-408. PubMed ID: 9442807
[No Abstract] [Full Text] [Related]
6. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.
Rouas-Freiss N; Moreau P; Menier C; LeMaoult J; Carosella ED
Semin Cancer Biol; 2007 Dec; 17(6):413-21. PubMed ID: 17881247
[TBL] [Abstract][Full Text] [Related]
7. HLA-G and cancer.
Carosella ED; Horuzsko A
Semin Cancer Biol; 2007 Dec; 17(6):411-2. PubMed ID: 17698367
[No Abstract] [Full Text] [Related]
8. Non-classical HLA-G antigen and its role in the cancer progression.
Tripathi P; Agrawal S
Cancer Invest; 2006 Mar; 24(2):178-86. PubMed ID: 16537188
[TBL] [Abstract][Full Text] [Related]
9. Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: evidence for an important role in the maternal tolerance of the fetal allograft.
Moreau P; Paul P; Rouas-Freiss N; Kirszenbaum M; Dausset J; Carosella ED
Am J Reprod Immunol; 1998 Sep; 40(3):136-44. PubMed ID: 9764357
[TBL] [Abstract][Full Text] [Related]
10. The HLA-G*0105N null allele induces cell surface expression of HLA-E molecule and promotes CD94/NKG2A-mediated recognition in JAR choriocarcinoma cell line.
Sala FG; Del Moral PM; Pizzato N; Legrand-Abravanel F; Le Bouteiller P; Lenfant F
Immunogenetics; 2004 Dec; 56(9):617-24. PubMed ID: 15578261
[TBL] [Abstract][Full Text] [Related]
11. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?
Wischhusen J; Waschbisch A; Wiendl H
Semin Cancer Biol; 2007 Dec; 17(6):459-68. PubMed ID: 17768067
[TBL] [Abstract][Full Text] [Related]
12. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
13. Role of HLA-G in innate immunity through direct activation of NF-kappaB in natural killer cells.
Guillard C; Zidi I; Marcou C; Menier C; Carosella ED; Moreau P
Mol Immunol; 2008 Jan; 45(2):419-27. PubMed ID: 17675239
[TBL] [Abstract][Full Text] [Related]
14. TH1/TH2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the TH1/TH2 paradigm.
Chaouat G; Ledée-Bataille N; Dubanchet S; Zourbas S; Sandra O; Martal J
Int Arch Allergy Immunol; 2004 Jun; 134(2):93-119. PubMed ID: 15153791
[TBL] [Abstract][Full Text] [Related]
15. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition.
Riteau B; Menier C; Khalil-Daher I; Martinozzi S; Pla M; Dausset J; Carosella ED; Rouas-Freiss N
Int Immunol; 2001 Feb; 13(2):193-201. PubMed ID: 11157852
[TBL] [Abstract][Full Text] [Related]
16. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers.
Zidi I; Guillard C; Marcou C; Krawice-Radanne I; Sangrouber D; Rouas-Freiss N; Carosella ED; Moreau P
Cell Mol Life Sci; 2006 Nov; 63(22):2669-81. PubMed ID: 17072500
[TBL] [Abstract][Full Text] [Related]
17. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.
Maki G; Hayes GM; Naji A; Tyler T; Carosella ED; Rouas-Freiss N; Gregory SA
Leukemia; 2008 May; 22(5):998-1006. PubMed ID: 18288133
[TBL] [Abstract][Full Text] [Related]
18. HLA-G and immune evasion in cancer cells.
Sheu J; Shih IeM
J Formos Med Assoc; 2010 Apr; 109(4):248-57. PubMed ID: 20434034
[TBL] [Abstract][Full Text] [Related]
19. Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules.
Le Friec G; Gros F; Sebti Y; Guilloux V; Pangault C; Fauchet R; Amiot L
J Leukoc Biol; 2004 Dec; 76(6):1125-33. PubMed ID: 15331623
[TBL] [Abstract][Full Text] [Related]
20. HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications.
Rebmann V; Nückel H; Dührsen U; Grosse-Wilde H
Semin Cancer Biol; 2007 Dec; 17(6):430-5. PubMed ID: 17683947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
